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40-word summary: In this European multicenter case-control study, Nocardia infection after organ 
transplantation was associated with high blood concentrations of calcineurin inhibitors, use of 
tacrolimus, dose of corticosteroids, patient age and length of stay in the intensive care unit after 
transplantation.  
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ABSTRACT  
Background. Nocardiosis is a rare, life-threatening opportunistic infection, affecting 0.04% to 3.5% of 
patients after solid organ transplantation (SOT). The aim of this study was to identify risk factors for 
Nocardia infection after SOT and to describe the presentation of nocardiosis in these patients. 
Methods. We performed a retrospective case-control study of adult patients diagnosed with 
nocardiosis after SOT between 2000 and 2014 in 36 European (France, Belgium, Switzerland, 
Netherlands, Spain) centers. Two control subjects per case were matched by institution, transplant 
date and transplanted organ. A multivariable analysis was performed using conditional logistic 
regression to identify risk factors for nocardiosis.  
Results. One hundred and seventeen cases of nocardiosis and 234 control patients were included. 
Nocardiosis occurred at a median of 17.5 [range 2-244] months after transplantation. In multivariable 
analysis, high calcineurin inhibitor trough levels in the month before diagnosis (OR=6.11 [2.58-
14.51]), use of tacrolimus (OR=2.65 [1.17-6.00]) and corticosteroid dose (OR=1.12 [1.03-1.22]) at the 
time of diagnosis, patient age (OR=1.04 [1.02-1.07]) and length of stay in intensive care unit after SOT 
(OR=1.04 [1.00-1.09]) were independently associated with development of nocardiosis; low-dose 
cotrimoxazole prophylaxis was not found to prevent nocardiosis. Nocardia farcinica was more 
frequently associated with brain, skin and subcutaneous tissue infections than were other Nocardia 
species. Among the 30 cases with central nervous system nocardiosis, 13 (43.3%) had no neurological 
symptoms. 
Conclusions. We identified five risk factors for nocardiosis after SOT. Low-dose cotrimoxazole was 
not found to prevent Nocardia infection. These findings may help improve management of transplant 
recipients. 
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LIST OF ABBREVIATIONS 
 
16S rRNA: 16S ribosomal ribonucleic acid 
95% CI:  95% confidence interval 
ATG:  antithymocyte globulin 
CMV:   cytomegalovirus 
CNS:  central nervous system 
COPD:   chronic obstructive pulmonary disease 
CRP:   C-reactive protein 
DNA:  deoxyribonucleic acid 
HIV:  human immunodeficiency virus 
ICU:  intensive care unit 
MALDI-TOF: matrix-assisted laser desorption/ionization time-of-flight 
MRI:  magnetic resonance imaging 
NS:  not significant 
OR:  odds ratio 
PCR:  polymerase chain reaction 
SOT:  solid organ transplantation 
spp.:  species 
TMP-SMX: trimethoprim–sulfamethoxazole (cotrimoxazole) 
USA:  United States of America
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INTRODUCTION 
Nocardia species (spp.) are ubiquitous environmental Gram-positive filamentous bacteria and can be 
responsible for severe opportunistic infections in humans [1]. Direct inoculation through the skin is 
possible [2], but most Nocardia infections occur via the respiratory tract, with possible subsequent 
dissemination to other tissues, such as brain, skin and subcutaneous tissues [1]. Nocardia can infect 
immunocompetent patients, but invasive nocardiosis is mainly observed in patients with immune 
deficiency [3], including that associated with corticosteroid therapy, transplantation, human 
immunodeficiency virus (HIV) infection [4, 5], cancer [6], chronic granulomatous disease [7] or 
presence of auto-antibodies against granulocyte-macrophage colony stimulating factor [8] and/or in 
patients with chronic lung disease [9, 10].  
Solid organ transplant recipients are at risk of opportunistic events, such as Nocardia 
infections [11], and nocardiosis has been described in these patients since the early years of solid 
organ transplantation (SOT) in the 1960s [12]. The risk of developing nocardiosis after SOT varies with 
the type of organ transplanted, the highest infection rates being observed after lung transplantation 
(estimates between 0.8% and 3.5%) and the lowest after liver and kidney transplantations (0.04-
1.2%) [13-19]. Nocardia infection after SOT is a severe disease associated with a mortality rate of 
about 20% [19]. Managing these opportunistic infections is difficult, especially because of the need 
for long-term treatment (usually 6 to 12 months) to avoid relapses, and the toxicity of the antibiotics, 
particularly when combined with immunosuppressive drugs [11].  
Despite these therapeutic challenges and poor outcomes, little is known about the risk 
factors for nocardiosis after SOT. Conducting prospective studies is difficult because of the low 
incidence of this infection. In 2007, Peleg and colleagues reported a case-control study of nocardiosis 
after SOT [15]. In this study, 35 cases and 70 controls were included and three factors were 
significantly associated with an increased risk of Nocardia infection: use of high-dose steroids, a high 
median calcineurin inhibitor level in the month prior to infection and cytomegalovirus (CMV) disease 
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in the preceding six months. This study provided considerable insight into our understanding of 
nocardiosis after SOT, but was conducted in a single center with a limited number of cases. To 
increase the statistical power to detect risk factors, we therefore conducted a retrospective case-
control study of Nocardia infections in a large number of SOT centers in Western Europe. 
Our main objective was to identify risk factors for Nocardia infections in SOT recipients. A 
secondary aim was to describe the clinical, biological and radiological presentation of nocardiosis in 
this population. 
 
MATERIAL & METHODS  
Study design, setting and participants 
This was an international nested case-control study. All Belgian, French and Swiss hospitals with an 
SOT program were asked to participate in the study and two other European transplantation centers 
also took part: Leiden University Medical Center (Leiden, The Netherlands) and University Hospital 12 
de Octubre (Madrid, Spain). To avoid selection bias, cases were identified in each institution using a 
systematic and comprehensive screening of local microbiological, pathology and transplantation 
databases. In France, the study was approved by the CPP Ile-de-France I Ethical board (March 7, 
2014). In other countries, the participating centers obtained approval from their respective Ethics 
Committees before joining the study.  
 
Inclusion criteria 
Patients meeting all the following criteria were included in the study: (1) SOT recipient; (2) Nocardia 
spp. isolated in a clinical sample after transplantation; (3) presence of signs and/or symptoms 
compatible with nocardiosis; (4) diagnosis made between January 2000 and December 2014. We 
selected two matched controls for each case. Matched controls were SOT recipients who: (1) had 
received the same type of transplanted organ in the same institution as the case; (2) had no evidence 
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of Nocardia infection up to the date of inclusion; (3) had received their transplant at about the same 
time as the case; (4) had survived as long as the case had prior to the diagnosis of Nocardia infection.  
 
Clinical data and definitions 
The date of diagnosis of nocardiosis was defined as the day on which the first clinical sample (e.g., 
sputum) yielding Nocardia spp. was collected. For control patients, a corresponding date was chosen 
on the basis of their matched case’s date of diagnosis, in order to obtain a similar period of time from 
transplantation. We collected demographic and transplant data with a specific focus on possible 
nocardiosis risk factors, such as type of organ donation, length of stay in the intensive care unit (ICU) 
after transplantation, need for post-transplantation dialysis or mechanical ventilation and co-
morbidities (chronic obstructive pulmonary disease [COPD], diabetes). Recorded therapeutic data 
included immunosuppressive regimen at the time of transplantation, occurrence and treatment of 
acute allograft rejection episodes between transplantation and the date of nocardiosis diagnosis 
(including use of high-dose corticosteroids [>20 mg/day of prednisone for at least 1 month or >2 
pulses of 500 mg of intravenous methylprednisolone [15]] and/or plasma exchange), presence of a 
high calcineurin inhibitor trough level in the month prior to diagnosis (defined as >10 µg/mL for 
tacrolimus and >300 ng/mL for cyclosporine) and receipt of trimethoprim-sulfamethoxazole (TMP-
SMX, cotrimoxazole) prophylaxis at the time of nocardiosis diagnosis. We also recorded any 
prescriptions of lymphocyte-depleting and/or modulating antibodies, such as antithymocyte globulin 
(ATG), rituximab or basiliximab/daclizumab, in the 12 months prior to diagnosis. Occurrence of 
bloodstream infections after transplantation was noted. Development of CMV infection and/or 
disease [20] between transplantation and date of diagnosis was recorded as were CMV serostatus 
and white blood cell counts at 1 and 2 months after transplantation and at 1 month before the 
diagnosis of nocardiosis. We also recorded clinical signs of nocardiosis, sites of infection, biological 
findings at the time of Nocardia infection (kidney function, C-reactive protein [CRP] level, leukocyte, 
neutrophil and lymphocyte counts), species identification and radiological findings. Dissemination 
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was defined as infection of at least two non-contiguous organs. Outcome was assessed by all-cause 
mortality 12 months after the diagnosis of nocardiosis. 
 
Microbiology 
To identify the species of each Nocardia strain, amplification and sequencing of a fragment of the 
gene coding for the 16S ribosomal RNA (16S rRNA) or hsp65 were mandatory [21]. Briefly, around 
500 base pairs of the 16S rRNA gene were sequenced using polymerase chain reaction (PCR), as 
described previously [22]. Sequences were compared with those stored in GenBank using blast 
alignment software (http://www.ncbi.nlm.nih.gov/blast) and BIBI (Bio Informatic Bacteria 
Identification tool; http://pbil.univ-lyon1.fr/bibi) [3]. Identification at the species level required 99% 
sequence similarity with the type strain of a single species. If required, the hsp65 gene was amplified 
and sequenced to allow adequate identification [23]. For strains that were not analyzed using 
molecular methods, species identification was not considered reliable. However, the Nocardia genus 
could be identified using a validated non-PCR method, such as matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) spectrometry or phenotypic testing showing 
aerobic filamentous and branching Gram-positive rods, lysozyme-resistant with aerial hypha [1, 24]. 
When needed, stored samples were sent a posteriori to the French expert laboratory for nocardiosis 
(Observatoire Français des Nocardioses, Lyon, France) to perform missing analyses and obtain 
molecular identification.  
 
Statistical analysis 
Final analysis was conducted after all data had been recorded and verified. Clinical, biological and 
radiological data of cases at the time of diagnosis are described. Continuous variables are presented 
as means (± standard deviation) or medians (range). Categorical variables are presented as numbers 
and frequencies. Associations between clinical and biological determinants and Nocardia infection 
were analyzed using univariate conditional logistic regression. A two-sided p-value < 0.05 was 
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considered as statistically significant. Clinical and therapeutic determinants with a p-value < 0.05 on 
univariate analysis were included in the final multivariable conditional logistic regression analysis. 
Because of the large amount of missing data, biological variables were not included in the final 
multivariable analysis. A systematic search for interaction between determinants with a p-value < 
0.05 on univariate analysis was performed. All statistical analyses were performed using R Statistical 
software (version 3.2.0; R Foundation for Statistical Computing, Vienna, Austria). 
 
RESULTS 
Characteristics of the patients 
We included a total of 117 cases of nocardiosis from 23 French (n=74), 7 Belgian (n=28), 4 Swiss 
(n=5), 1 Dutch (n=7) and 1 Spanish (n=3) transplant centers, and 234 matched controls. Only one of 
these cases has been reported previously [25]. The patients’ characteristics are shown in Table 1. The 
kidney was the most frequently transplanted organ (n=69, 59%), followed by the heart (n=23, 19.7%), 
lung (n=16, 13.7%), pancreas (n=4, 3.4%) and liver (n=4, 3.4%). A single patient (0.9%) received 
combined organs at transplantation. Nocardiosis occurred at a median of 17.5 months [range 2-244] 
after SOT. Forty-eight of the cases of nocardiosis (41%) were diagnosed within the first year after 
transplantation while 37 (31.6%) occurred at least 3 years after transplantation (Figure 1). The length 
of time between transplantation and diagnosis of nocardiosis was statistically different for the 
different organs (heart: median 10 months [3-198]; lung: 17 months [2-106]; and kidney: 20 months 
[2-244]; p=0.035, Kruskal-Wallis test). 
 
Characteristics and outcome of post-transplant nocardiosis 
The clinical, biological and radiological characteristics of the nocardiosis cases are shown in Table 2. 
The most frequent clinical presentation was pulmonary disease (101/117, 86.3%) and in 55 (54.5%) 
of these cases the lung was the only site of infection. Among the patients with lung involvement, a 
lung computed tomography (CT)-scan was performed for initial workup in 91 cases (90.1%) and 
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showed nodule(s) as the most commonly observed feature (68/91, 74.7%), 32.3% of which were 
cavitated. Brain imaging (magnetic resonance imaging [MRI] and/or CT-scan) was performed in 90 of 
the patients (76.9%). Among the 30 patients in whom central nervous system (CNS) nocardiosis was 
demonstrated on imaging, 13 (43.3%) had no neurological abnormalities on clinical examination. 
Reliable species identification was obtained using molecular biology tools in 105 of the 117 
cases (89.7%). N. farcinica, N. nova complex and N. cyriacigeorgica were the most frequently 
identified species, responsible for 35% (41/117), 24% (28/117), and 7% (8/117) of the cases, 
respectively (Figure 2). Nocardiosis caused by N. farcinica more frequently involved the brain (16/41 
[39%] versus 14/76 [18%]) and the skin and soft tissues (20/41 [49%] versus 17/76 [22%]), than did 
nocardiosis caused by other species (p<0.05, Chi-square test) (Table S1 - Appendix).  
Twelve months after the diagnosis of nocardiosis or the equivalent period for the controls, 
the all-cause mortality rate was 16.2% (19/117) among cases and 1.3% (3/233) among controls 
(p<0.001 Fisher’s exact test). Among the 98 nocardiosis cases alive at 12 months, the median follow-
up was 51 months [12-151]; six patients [6.1%] had a relapse during follow-up.   
 
Risk factors for nocardiosis 
In univariate analysis (Table 1), recipient age at diagnosis, donor age, length of stay in the ICU after 
transplantation, comorbid diabetes, history of bloodstream infection between transplantation and 
nocardiosis and acute rejection in the six months before nocardiosis were significantly associated 
with the development of nocardiosis. High trough blood concentrations of calcineurin inhibitors in 
the month before Nocardia infection, use of tacrolimus at the time of diagnosis, a high dose of 
corticosteroids at the time of diagnosis, high dose corticosteroids in the six months before 
nocardiosis and use of plasma exchange or depleting antibodies in the six months prior to infection 
were also significantly associated with Nocardia infection. Regarding CMV, D+R- serostatus was 
significantly associated with the occurrence of nocardiosis in univariate analysis. Patients with 
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nocardiosis had significantly lower lymphocyte counts two months after transplantation and one 
month before diagnosis than did the control patients.  
In the multivariable analysis, high blood calcineurin inhibitor trough levels in the month 
before diagnosis, use of tacrolimus at the time of diagnosis, corticosteroid dose at the time of 
diagnosis, patient age and length of stay in the ICU after SOT were significantly associated with the 
development of nocardiosis (Table 3). Nocardiosis did not occur earlier in patients who had a short 
length of stay in the ICU after SOT (<8 days), when compared with those with a long length of stay 
(≥8 days): 17 [1-65] vs. 20 [3-195] months after transplantation, respectively (p=NS, Kruskal-Wallis 
test).   
 
Effect of anti-Pneumocystis prophylaxis with cotrimoxazole on the risk of nocardiosis 
Twenty-one of the nocardiosis cases (18%) were receiving anti-Pneumocystis prophylaxis with TMP-
SMX at the time of diagnosis compared with 57 (24.5%) of the control patients (OR, 0.36; 95% CI, 
0.14-0.93; p=0.03). In multivariable analysis, use of TMP-SMX prophylaxis was not found to be 
protective against occurrence of nocardiosis. The mean weekly dose of SMX was 1819 (±668) mg in 
cases vs. 2161 (±957) mg in control patients (p=NS). Among the 351 patients, only two of the control 
patients (0.6%) were receiving high-dose prophylaxis (i.e., 160/800 mg of TMP-SMX daily). 
Regarding the 21 episodes of nocardiosis breaking through TMP-SMX prophylaxis, antimicrobial 
testing was performed on 19 of these cases (90.5%) and 15/19 isolates (78.9%) were susceptible to 
TMP-SMX.  
 
DISCUSSION 
We report the results from the first multicenter case-control study on nocardiosis after SOT. We 
describe the clinical, biological and radiological presentations of Nocardia infection and identified 5 
variables that were significantly associated with the occurrence of this opportunistic event in 
multivariable analysis: a high blood trough level of calcineurin inhibitor in the month before 
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diagnosis, use of tacrolimus at the time of diagnosis, corticosteroid dose at the time of diagnosis, 
patient age and length of stay in the ICU after transplantation.  
Although nocardiosis is an opportunistic infection that has been described since the very 
early years of SOT, there are a number of unsolved issues that still need to be addressed. Indeed, 
most of the publications on this topic have been case reports or small, uncontrolled series that did 
not allow evaluation of the risk factors that may lead to post-transplant nocardiosis. However, 
identifying risk factors in this population is important because Nocardia infection is a rare but life-
threatening event and patients could benefit from prevention, early diagnosis and appropriate 
treatment. In a case-control study in a single center in Pittsburgh (USA), Peleg and colleagues 
identified three risk factors for nocardiosis: use of high-dose steroids, a high calcineurin inhibitor 
level in the month prior to diagnosis and CMV disease in the 6 months prior to diagnosis [15]. 
 Although our two studies differ in location (USA vs. Europe), study period (1995-2005 vs. 
2000-2014) and design (single center vs. multicenter), both indicate that a high degree of immune 
suppression (i.e., high exposure to calcineurin inhibitors and corticosteroids) plays a key role in the 
development of nocardiosis in SOT recipients. Furthermore, we showed that use of tacrolimus (a 
variable that was not recorded by Peleg and coworkers) was independently associated with 
development of nocardiosis, as has been previously suggested [26, 27]. Interestingly, previous 
studies have reported a protective role of tacrolimus against the development of opportunistic fungal 
infections, including Pneumocystis jirovecii pneumonia and mucormycosis [28, 29]. This apparent 
discrepancy may be explained by a direct anti-fungal effect of tacrolimus or by the inhibition of a 
specific anti-Nocardia T-cell or macrophage function [30]. Alternatively, tacrolimus use may reflect a 
greater state of overall immunosuppression as this drug is often used in patients at high risk of graft 
rejection [31, 32].   
In contrast to Peleg and colleagues who identified CMV disease as a risk factor for 
nocardiosis, CMV serostatus and CMV disease or infection were not significantly associated with 
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development of Nocardia infection in our study. This observation may be due to differences in the 
definitions of and use of prevention strategies for CMV infection and disease between our studies.  
We also identified older patient age and longer length of stay in the ICU after transplantation 
as risk factors for nocardiosis. Interestingly, we observed no significant difference when comparing 
the time between transplantation and the occurrence of nocardiosis between patients who had a 
short length of stay in the ICU after SOT (<8 days) and those with a long length of stay (≥8 days). 
Therefore, these factors may reflect a general frailty of the recipient, making them more likely to 
develop complications after transplantation.    
No intervention has yet been shown to prevent nocardiosis in transplant recipients. 
Interestingly, administration of TMP-SMX (the most common treatment for nocardiosis) as 
prophylaxis against pneumocystosis was not found to effectively prevent nocardiosis in our study, or 
in the study by Peleg et al. [15], although our study design does not allow definitive conclusions to be 
drawn regarding the use of TMP-SMX for this purpose. As described elsewhere, we have observed 
that occurrence of TMP-SMX-susceptible Nocardia infections was common in subjects receiving this 
agent as prophylaxis against pneumocystosis, suggesting that resistance to TMP-SMX was not 
responsible for the breakthrough nocardiosis [3, 14, 17]. A possible explanation for this lack of 
prophylactic effect is that the relatively low dose of TMP-SMX used to prevent pneumocystosis may 
be insufficient to prevent Nocardia infection. Indeed, HIV-infected patients, who usually receive a 
higher weekly dose of TMP-SMX, have a lower incidence of nocardiosis compared to SOT recipients 
[33]. Although the mean weekly dose of TMP-SMX was similar in cases and controls, it is difficult to 
interpret these data, because renal function, body weight and compliance also need to be taken into 
account.  
No clinical, biological or radiological signs were specific for nocardiosis, but pulmonary 
nocardiosis (the most common presentation in our cohort) was associated with nodule(s) in 68/91 
(74.7%) patients. Therefore, a nodular pneumonia occurring after SOT should raise suspicion of 
possible nocardiosis. Furthermore, our study demonstrated that CNS nocardiosis is common 
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(detected in 30/117 patients, 25.6%) and that in many of the patients with CNS nocardiosis, 
neurological clinical examination is normal. The latter observation suggests that brain imaging is 
justified in any SOT recipient with nocardiosis [11].   
Once nocardiosis is suspected and confirmed in the microbiology laboratory, identification of 
Nocardia at the species level requires molecular tools, such as amplification and sequencing of the 
gene coding for the 16S rRNA or hsp65. Using such approaches, it has been shown that N. asteroides 
–the most frequently identified species until the end of the 1990s- is an uncommon cause of 
nocardiosis [19]. Because each species has its own antimicrobial susceptibility profile, accurate 
identification can help guide choice of empirical antibiotic therapy [1]. Previous studies of post-
transplant nocardiosis rarely used sequencing as an identification tool, resulting in the frequent and 
incorrect identification of N. asteroides. In our study, partial sequencing was performed in 105/117 of 
our strains (89.7%). N. farcinica and N. nova complex were the two most frequently isolated species, 
identified in 35% (41/117) and 24% (28/117), respectively, of our European cases of nocardiosis after 
SOT. We identified no cases of N. asteroides. 
Our retrospective study has several limitations. First, it was not possible to evaluate the role 
of potential risk factors that were not recorded in patients’ medical records (e.g., environmental 
exposure to soil or decaying vegetation). Second, there were some missing data (Table 1), so we 
were unable to analyze the role of biological variables in our multivariable analysis. However, 
conducting a prospective cohort study was considered impractical because of the rarity of post-SOT 
nocardiosis.  
Interestingly, the all-cause mortality rate was 16.2% (19/117) in our cohort, a finding that is 
compatible with previous studies in which the mortality rate was about 20% [19], suggesting that our 
cohort is representative of the population of solid organ transplant recipients with nocardiosis in 
western countries. 
In conclusion, a high calcineurin inhibitor trough level in the month prior to diagnosis, use of 
tacrolimus at the time of diagnosis, corticosteroid dose at the time of diagnosis, patient age and 
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length of stay in the ICU after transplantation were independent risk factors for nocardiosis after 
SOT. At the doses used in our cohort, cotrimoxazole was not found to prevent development of 
nocardiosis. Further studies are needed to assess the benefits and disadvantages of higher doses of 
TMP-SMX in the prevention of Nocardia infection in high-risk patients and to evaluate the outcome 
of patients with post-transplant nocardiosis.   
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Figure 1. Distribution of the time (in months) between solid organ transplantation and the occurrence of 
nocardiosis in the 117 cases. Dashed line represents the median time point (17.5 months) 
 
Figure 2. Distribution of the various Nocardia species identified using molecular biology in the 117 cases of 
post-transplantation nocardiosis. *Other species include N. otitidiscaviarum (n=1), N. brevicatena/paucivorans 
complex (n=1), N. cerradoensis (n=1), N. pseudobrasiliensis (n=1), N. anaemiae (n=1), N. takedensis (n=1).  
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Table 1. Clinical and biological characteristics of cases and controls up to the diagnosis of nocardiosis 
Characteristics 
 
Cases 
(n=117) 
 
Controls 
(n=234) 
OR 
[IC95%] 
Univariate analysis 
p-value 
Clinical characteristics     
 Age at diagnosis (years) (mean ± SD) 55.6 ± 13.5 50.7 ± 13.5 1.04 [1.02-1.06] <0.001 
 Male  74 (63.2) 150 (64.1) 0.96 [0.59-1.55] 0.87 
 Number of transplants     
 1st 99 (84.6) 211 (90.2)   
 2nd or 3rd  18 (14.5) 23 (7.7) 1.84 [0.88-3.82] 0.10 
 Donor age (mean ± SD) n=332 47.5 ± 16.9 43.3 ± 25.0 1.02 [1.00-1.04] 0.02 
 Deceased donor (vs. living) n=349 107 (91.5) 217 (93.5) 1.41 [0.58-3.43] 0.44 
 Length of stay in the ICU after transplantation (days) (mean ± SD) n= 343 7.9 ± 9.8 6.2 ± 8.6 1.04 [1.00-1.07] 0.04 
 COPD after transplant n=350 11 (9.4) 17 (7.3) 1.40 [0.58-3.35] 0.45 
 Dialysis post-transplant n=348 23 (19.8) 40 (17.2) 1.22 [0.68-2.17] 0.51 
 Mechanical ventilation post-transplant n=347 28 (24.6) 61 (26.3) 0.74 [0.29-1.88] 0.53 
 Diabetes at diagnosis n=350 43 (37.7) 54 (23.2) 1.91 [1.17-2.10] 0.01 
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 Acute rejection episode in the 6 months before diagnosis n=350 25 (21.6) 29 (12.4) 2.56 [1.23-5.33] 0.01 
 CMV infection in the 6 months before diagnosis n=350 17 (14.5) 24 (10.3) 1.70 [0.78-3.73] 0.18 
 CMV disease in the 6 months before diagnosis n=350 5 (4.27) 5 (2.15) 2.20 [0.58-8.36] 0.25 
 CMV Serostatus n=340     
  D-R- 22 (19.5) 68 (29.8)   
  D-R+ or D+R+ 60 (51.3) 120 (51.3) 1.66 [0.91-3.04] 0.10 
  D+R- 31 (27.4) 40 (17.5) 2.65 [1.32-5.31] 0.01 
 Bloodstream infection before diagnosis n=350 25 (21.4) 28 (12.0) 2.05 [1.10-3.80] 0.02 
Therapeutic characteristics     
 Immunosuppressive induction n=342     
  None 5 (4.4) 18 (7.9)   
  ATG 77 (68.1) 137 (59.8) 3.39 [0.72-16.00] 0.12 
  Anti-CD25 31 (27.4) 74 (32.3) 1.83 [0.35-9.57] 0.47 
 Corticosteroid bolus at transplant (mg) (mean ± SD) n=339 518 ± 235 541 ± 257 1.00 [1.00-1.00] 0.24 
 Corticosteroids at M1 (mg†) (mean ± SD) n=335 17.5 ± 11.4 17.1 ± 11.4 1.01 [0.98-1.04] 0.64 
 Corticosteroids at M2 (mg†) (mean ± SD) n=340 13.6 ± 10.3 12.4 ± 8.3 1.04 [1.00-1.09] 0.06 
 Corticosteroids at diagnosis (mg†) (mean ± SD) n=342 8.8 + 6.8 6.5 ± 5.2 1.16 [1.08-1.25] <0.001 
 High-dose steroids in the 6 months before diagnosis n=350 20 (17.2) 16 (6.8) 3.56 [1.58-8.01] 0.002 
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 CsA at diagnosis n=350 21 (18.0) 71 (30.5) 0.38 [0.19-0.74] 0.005 
 Tacrolimus at diagnosis n=350 93 (79.5) 143 (61.4) 3.73 [1.88-7.41] <0.001 
 High CNI blood level in the month before diagnosis n=349 51 (43.6) 40 (17.2) 7.29 [3.51-15.15] <0.001 
 AZA at diagnosis n=350 16 (13.7) 27 (11.6) 1.3 [0.60-2.81] 0.50 
 MMF at diagnosis n=350 79 (67.5) 175 (75.1) 0.61 [0.34-1.08] 0.09 
 Use of antiproliferative agents (AZA or MMF) at diagnosis n=350 95 (81.2) 202 (86.7) 0.59 [0.30-1.19] 0.14 
 Plasma exchange in the 6 months before diagnosis n=350 5 (4.3) 0 (0) NC 0.004 
 Depleting antibodies (ATG or Rituximab)* in the 6 months before 
diagnosis n=350 
6 (5.2) 3 (1.3) 5.31 [1.06-26.77] 0.04 
 Depleting antibodies (ATG or Rituximab)* in the 12 months before  
diagnosis n=350  
TMP-SMX prophylaxis at diagnosis n=350 
7 (6) 
 
21 (18.0) 
3 (1.3) 
 
57 (24.5) 
11.13 [1.34-92.45] 
 
0.36 [0.14-0.93] 
0.03 
 
0.03 
Biological characteristics     
 WBC count at M2 (x1000/mm3) (mean ± SD) n=344 7.5 ± 4.0 7.2 ± 2.7 1.03 [0.95-1.11] 0.49 
 WBC count 1 month before diagnosis (x1000/mm3) (mean ± SD) n=327 8.3 ± 3.9 7.2 ± 2.5 1.13 [1.04-1.23] 0.004 
 Lymphocyte count at M2 (x1000/mm3) (mean ± SD) n=304 0.8 ± 0.6 1.0 ± 0.7 0.47 [0.29-0.78] 0.003 
 Lymphocyte count 1 month before diagnosis (x1000/mm3) (mean ± SD) 
n=299 
0.7 ± 0.5 1.3 ± 0.9 0.22 [0.29-0.78] <0.001 
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 Neutrophil count at M2 (x1000/mm3) (mean ± SD) n=301 5.7 ± 3.6 5.5 ± 2.5 1.02 [0.92-1.12] 0.74 
 Neutrophil count 1 month before diagnosis (x1000/mm3) (mean ± SD) 
n=300 
6.5 + 3.7 5.2 ±2.2 1.19 [1.08-1.31] <0.001 
NOTE. ATG: antithymocyte globulin; AZA: azathioprine; CMV: cytomegalovirus; CNI: calcineurin inhibitor; COPD: chronic obstructive pulmonary disease; CsA: 
ciclosporin A; diagnosis: date of the diagnosis of nocardiosis; ICU: intensive care unit; M1: one month after transplantation; M2: two months after 
transplantation; MMF: mycophenolate mofetil; n: number of data analyzed (when <351); NA: not analyzed; OR: Odds ratio; SD: standard deviation; TMP-SMX: 
trimethoprim–sulfamethoxazole; WBC: white blood cell.  
Data are n (%) unless otherwise indicated. † All the corticosteroid doses are expressed in milligrams (mg) of methylprednisolone equivalent per day. *In the 12 
months before diagnosis of Nocardia infection, none of our patients received other types of lymphocyte-depleting or modulating antibodies. 
 
 at E-Library Insel on M
ay 23, 2016
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
29 
 
Table 2. Description of the 117 cases of post-transplantation nocardiosis at diagnosis 
 
Characteristics 
 
117 cases 
Clinical characteristics   
 Time from onset of symptoms to diagnosis (days) (median, range) 19.5 [1-139] 
 Involved organs   
  Lung 101 (86.3) 
  Skin and soft-tissue 37 (31.6) 
  
Skin and soft-tissue as the only site of infection 
Brain 
8 (6.8) 
30 (25.6) 
  Joint(s) or bone(s) 3 (2.5) 
 Disseminated infection  50 (42.7) 
 Clinical signs   
  Fever > 38°C 71 (60.7) 
  Chills 25 (21.4) 
  Weight loss (n=115) 40 (34.8) 
  Asthenia (n=116) 74 (63.8) 
  Dyspnea (n=116) 48 (41.4) 
  Chest pain (n=116) 28 (24.1) 
  Cough (n=116) 65 (56) 
  Sputum production (n=115) 43 (37.4) 
  Acute respiratory distress† (n=116) 5 (4.3) 
  Headache (n=116) 15 (12.9) 
  Coma (n=116) 3 (2.6) 
  Seizures (n=116) 9 (7.8) 
  Focal neurological signs (n=116) 11 (9.5) 
  Cutaneous lesions (n=116) 37 (31.9) 
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  Arthritis (n=116) 1 (1) 
Biological characteristics on the day of diagnosis   
 White blood cell count (x1000/mm3) (mean ± SD) (n=115) 11.5 ± 6.5 
 Neutrophil count (x1000/mm3) (mean ± SD) (n=105) 9.7 ± 6.5 
 Lymphocyte count  (x1000/mm3) (mean ± SD) (n=106) 1.3 ± 0.8 
 Glomerular filtration rate ¶ (ml/min/1.73m2) (mean ± SD) (n=116) 48.6 ± 27.2 
 C-reactive protein (mg/l) (median, range) (n=109) 104 [1-469] 
Radiological characteristics   
 Type of lung involvement (n=91)  
  Nodules 68 (74.7) 
  Among nodules, cavitation (n=68) 22 (32.3) 
  Lung consolidation 37 (40.6) 
  Pleural effusion 24 (26.4) 
  Interstitial syndrome 11 (12.1) 
  No other lesions than interstitial syndrome 2 (2.2) 
  Multilobar involvement 51 (56) 
  Bilateral involvement 46 (50.5) 
 Type of brain abscess (n=30)  
  Multiple lesions 24 (80) 
  Bihemispheric 16 (53.3) 
  Supratentorial 28 (93.3) 
  Infratentorial 9 (30) 
Microbiological characteristics   
 Source of the culture that grew Nocardia*  
  Bronchoalveolar lavage 51 (43.6) 
  Sputum 25 (21.4) 
  Bronchial aspirate 23 (19.6) 
  Pleural fluid 8 (6.8) 
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  Transbronchial biopsy 6 (5.1) 
  Surgical or percutaneous lung biopsy 4 (3.4) 
  Abscess fluid 29 (24.8) 
  Cutaneous biopsy 11 (9.4) 
  Blood culture 9 (7.7) 
  Cerebrospinal fluid 2 (1.7) 
 At least one positive respiratory, lung or pleural sample 79 (67.5) 
 Positive direct examination 59 (50.4) 
 NOTE. Data are n (%) unless otherwise indicated.  
† If mechanical ventilation was required, ¶ as estimated by MDRD formula, *Each patient 
could have several positive samples. n: number of data analyzed (when <117) 
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Table 3. Risk factors for nocardiosis in 117 cases compared to 234 controls after multivariable analysis by 
conditional logistic regression 
Characteristic 
 
OR [95%IC] 
 
p-value 
 
High calcineurin inhibitor level in the month before nocardiosis 
 
6.11 [2.58-14.51] 
 
<0.001 
Use of tacrolimus at diagnosis  2.65 [1.17-6.00] 0.015 
Corticosteroid dose at diagnosis (per mg†) 1.12 [1.03-1.22] 0.002 
Age at diagnosis (per year) 1.04 [1.02-1.07] <0.001 
Length of first ICU stay after transplantation (per day) 1.04 [1.00-1.09] 0.049 
 
NOTE. Diagnosis: date of the diagnosis of nocardiosis; ICU: intensive care unit; OR: Odds ratio 
† Expressed in milligrams (mg) of methylprednisolone equivalent per day 
High calcineurin inhibitor level was defined as a trough blood level > 10 μL/mL for tacrolimus and > 300 
ng/mL for cyclosporine 
Because of the large number of missing data, biological variables were not included in the multivariable 
analysis 
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